What are the risks and benefits of long-acting anticholinergics in patients with asthma?
Metadata[+] Show full item record
Long-acting anticholinergics (LAAchs) have been demonstrated to improve peak expiratory flow (PEF) and forced expiratory volume over 1 second (FEV1) in patients with asthma. (SOR: C, based on disease-oriented outcomes.) They produce a small improvement in symptoms when added to inhaled steroid therapy, similar to that achieved by adding a long-acting beta-agonist. (SOR: B, based on a single RCT.) However, long-term safety is unclear.
Evidence Based Practice 14(8): 08-09.